solute carrier family 66 member 1Genealiases: LAAT-1 · LAAT1 · PQLC2
Q-omics provides the consensus-scored SLC66A1 profile across patient tissues and cancer cell-line models. SLC66A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SLC66A1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, SLC66A1 RNA expression shows 17,913 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, BLCA, and ACC as cancer lineages where SLC66A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC66A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC66A1 survival associations across molecular data types. SLC66A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC66A1 RNA expression–survival associations across cancer types. High SLC66A1 expression shows unfavorable associations in LIHC, KICH, KIRC, LGG and BLCA, but favorable associations in COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SLC66A1 RNA expression.
This table summarizes SLC66A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC66A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC66A1 shows higher tumor expression in BLCA, HNSC, KIRC, KIRP, LIHC and THCA. The BLCA box plot shows higher SLC66A1 RNA expression in tumor versus normal tissue (log2 FC = +1.355, t-test p < 0.001).
This table shows molecular features associated with SLC66A1 in patient tissues and cancer cell lines. In patient samples, SLC66A1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC66A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
